Pogribny I P, Pogribna M, Christman J K, James S J
Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, Arkansas 72079, USA.
Cancer Res. 2000 Feb 1;60(3):588-94.
It is not known whether transcriptional suppression by de novo methylation occurs within the promoter region of the p53 gene during multistage tumorigenesis. To address this question, in vivo alterations in the CpG methylation within the rat p53 promoter region were evaluated in control, preneoplastic, and tumor tissue during tumor progression using the folate/methyl-deficient model of hepatocarcinogenesis. Alterations in CpG methylation were found to be site-specific and to vary depending on the stage of carcinogenesis. To further explore the effect of site-specific methylation on p53 promoter activity, reporter gene constructs were prepared containing specifically methylated sites within the p53 promoter region, and the transcriptional activity in cultured mammalian cells was determined in a transient transfection assay. Relative to the unmethylated construct as a positive control, single-site methylation at nucleotide (nt) -450, which occurs 216 nt upstream from the 85-nt minimal promoter region, suppressed promoter activity by 85%. In contrast, single-site methylation at nt -179, which occurs within the minimal essential promoter region, suppressed activity by only 20%. The p53 promoter constructs containing the singly methylated CpG site at nt -450 were then reevaluated for processive changes in methylation status 48 h after transfection, during maximum suppression of promoter activity. Restriction analysis with methylation-sensitive enzymes revealed that de novo methylation had occurred after transfection at previously unmethylated sites. These findings suggest that nt -450 may constitute a critical site for initiation of de novo methylation and processive spreading of methylation associated with transcriptional inactivation of the p53 gene. Furthermore, the results suggest a possible alternative mechanism for the silencing of the p53 gene in tumors that do not have p53 mutations.
在多阶段肿瘤发生过程中,p53基因启动子区域是否会发生从头甲基化导致的转录抑制尚不清楚。为了解决这个问题,我们利用肝癌发生的叶酸/甲基缺乏模型,评估了大鼠p53启动子区域CpG甲基化在肿瘤进展过程中在对照、癌前和肿瘤组织中的体内变化。发现CpG甲基化的变化具有位点特异性,并随致癌作用的阶段而变化。为了进一步探究位点特异性甲基化对p53启动子活性的影响,我们制备了在p53启动子区域含有特定甲基化位点的报告基因构建体,并通过瞬时转染实验测定了其在培养的哺乳动物细胞中的转录活性。相对于作为阳性对照的未甲基化构建体,位于核苷酸(nt)-450处的单一位点甲基化(位于85 nt最小启动子区域上游216 nt处)使启动子活性降低了85%。相比之下,位于nt -179处的单一位点甲基化(位于最小必需启动子区域内)仅使活性降低了20%。然后,在转染后48 h,在启动子活性受到最大抑制期间,对含有nt -450处单甲基化CpG位点的p53启动子构建体进行甲基化状态的连续变化再评估。用甲基化敏感酶进行的限制性分析表明,转染后在先前未甲基化的位点发生了从头甲基化。这些发现表明,nt -450可能是p53基因转录失活相关的从头甲基化起始和甲基化连续扩散的关键位点。此外,结果提示在没有p53突变的肿瘤中,p53基因沉默可能存在一种可能的替代机制。